镭-223在骨转移患者中的效用。
Usefulness of radium-223 in patients with bone metastases.
作者信息
Gupta Nishant, Devgan Arushi, Bansal Itisha, Olsavsky Thomas D, Li Shuo, Abdelbaki Ahmed, Kumar Yogesh
机构信息
Department of Radiology, Columbia University Medical Center, New York, New York (Gupta); Department of Radiology, University of Arkansas, Little Rock, Arkansas (Devgan); Department of Anesthesiology, New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York (Bansal); Department of Nuclear Medicine, St. Vincent's Medical Center, Bridgeport, Connecticut (Olsavsky); Department of Radiology, Yale New Haven Health at Bridgeport Hospital, Bridgeport, Connecticut (Li, Abdelbaki); and Columbia University at Bassett Healthcare, Cooperstown, New York (Kumar).
出版信息
Proc (Bayl Univ Med Cent). 2017 Oct;30(4):424-426. doi: 10.1080/08998280.2017.11930213.
Abstract
Castration-resistant prostate osseous metastases can be challenging to treat. There is a new era of clinical advancement with the Food and Drug Administration approval of radium-223 for use in these patients. Radium-223 is the only clinically used therapeutic radiopharmaceutical that emits alpha particles, making it extremely safe for therapeutic purposes for the patient as well as close contacts. This review discusses radium-223's mechanism of action, pharmacokinetics, indications, and safety profile, as well as findings of concluded clinical trials.
摘要
去势抵抗性前列腺骨转移瘤的治疗颇具挑战性。随着美国食品药品监督管理局批准镭-223用于治疗这些患者，临床进展进入了一个新时代。镭-223是唯一临床上使用的发射α粒子的治疗性放射性药物，这使其对患者及其密切接触者而言在治疗用途上极其安全。本综述讨论了镭-223的作用机制、药代动力学、适应证、安全性概况以及已完成临床试验的结果。
相似文献
1
Usefulness of radium-223 in patients with bone metastases.镭-223在骨转移患者中的效用。
Proc (Bayl Univ Med Cent). 2017 Oct;30(4):424-426. doi: 10.1080/08998280.2017.11930213.
2
Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.二氯化镭-223治疗骨转移性去势抵抗性前列腺癌：安全性评估
Expert Opin Drug Saf. 2015 Jul;14(7):1127-36. doi: 10.1517/14740338.2015.1045874. Epub 2015 May 28.
3
Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.二氯化镭-223：一种用于有症状骨转移的去势抵抗性前列腺癌患者的新型治疗选择。
Ann Pharmacother. 2015 Apr;49(4):469-76. doi: 10.1177/1060028014565444. Epub 2015 Jan 8.
4
Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.二氯化镭-223治疗转移性去势抵抗性前列腺癌：泌尿外科医生的观点
Urology. 2015 Apr;85(4):717-24. doi: 10.1016/j.urology.2014.11.031. Epub 2015 Feb 11.
5
Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.放射性核素 α 粒子药物治疗骨转移：氯化镭-223（Alpharadin）作用机制及辐射防护。
Oncology (Williston Park). 2012 Apr;26(4):330-7, 341.
6
Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.α发射体镭-223在实体瘤治疗中的应用：现状与未来方向
Am Soc Clin Oncol Educ Book. 2014:e132-9. doi: 10.14694/EdBook_AM.2014.34.e132.
7
Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.接受二氯化镭-223治疗的去势抵抗性前列腺癌患者的护理管理
Clin J Oncol Nurs. 2015 Apr;19(2):E31-5. doi: 10.1188/15.CJON.E31-E35.
8
Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.镭-223 在转移性去势抵抗性前列腺癌中的最佳应用。
J Formos Med Assoc. 2017 Nov;116(11):825-836. doi: 10.1016/j.jfma.2017.04.005. Epub 2017 Oct 16.
9
Radium-223 dichloride therapy in breast cancer with osseous metastases.二氯化镭-223治疗伴有骨转移的乳腺癌
BMJ Case Rep. 2015 Nov 18;2015:bcr2015211152. doi: 10.1136/bcr-2015-211152.
10
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.镭-223在转移性去势抵抗性前列腺癌不断增加的治疗手段中的新作用。
Expert Opin Pharmacother. 2017 Jun;18(9):899-908. doi: 10.1080/14656566.2017.1323875. Epub 2017 May 8.
引用本文的文献
1
Role of Radioiodine in Cancer Therapy: A Review of the Design and Challenges in Selecting Radioligands from Natural Sources.放射性碘在癌症治疗中的作用：从天然来源选择放射性配体的设计与挑战综述。
Drug Des Devel Ther. 2025 Sep 9;19:8009-8039. doi: 10.2147/DDDT.S524612. eCollection 2025.
2
Evaluation of Ce/La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer.用于前列腺癌正电子发射断层显像及俄歇电子治疗的铈/镧-PSMA-617评估
J Nucl Med. 2025 Aug 1;66(8):1252-1257. doi: 10.2967/jnumed.125.269751.
3
The Advancement of Targeted Alpha Therapy and the Role of Click Chemistry Therein.靶向α治疗的进展及其点击化学在其中的作用。
Molecules. 2025 Mar 13;30(6):1296. doi: 10.3390/molecules30061296.
4
Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments.去势抵抗性前列腺癌：从未被揭示的抵抗机制到当前的治疗方法
Cancers (Basel). 2023 Oct 19;15(20):5047. doi: 10.3390/cancers15205047.
5
The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker.治疗诊断用放射性药物的化学支架：放射性核素、双功能螯合剂和药代动力学修饰连接子。
Molecules. 2022 May 10;27(10):3062. doi: 10.3390/molecules27103062.
6
Single-center developing country analysis of radium-223 therapy in prostate cancer-preliminary results.前列腺癌镭-223治疗的单中心发展中国家分析——初步结果
Am J Nucl Med Mol Imaging. 2021 Oct 15;11(5):352-362. eCollection 2021.
7
The Potential Use of 11C-Choline Positron Emission Tomography/Computed Tomography to Monitor the Treatment Effects of Radium-223 in a Patient with Prostate Cancer.11C-胆碱正电子发射断层扫描/计算机断层扫描在监测一名前列腺癌患者镭-223治疗效果中的潜在应用
Cureus. 2018 Jul 9;10(7):e2948. doi: 10.7759/cureus.2948.
本文引用的文献
1
Contemporary agents in the management of metastatic castration-resistant prostate cancer.转移性去势抵抗性前列腺癌治疗中的当代药物
Can Urol Assoc J. 2016 Nov-Dec;10(11-12):E414-E423. doi: 10.5489/cuaj.4112. Epub 2016 Dec 12.
2
Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.镭-223 二氯化物（Ra-223）对住院的影响：来自 3 期随机 ALSYMPCA 试验中放射性配体治疗的疗效研究。
Eur J Cancer. 2017 Jan;71:1-6. doi: 10.1016/j.ejca.2016.10.020. Epub 2016 Dec 6.
3
Radium-223 Therapy of Bone Metastases in Prostate Cancer.镭-223治疗前列腺癌骨转移
Semin Nucl Med. 2016 Nov;46(6):544-556. doi: 10.1053/j.semnuclmed.2016.07.007. Epub 2016 Sep 15.
4
Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation.镭-223治疗转移性去势抵抗性前列腺癌患者：文献综述及病例报告
Int J Mol Imaging. 2016;2016:2568031. doi: 10.1155/2016/2568031. Epub 2016 Sep 27.
5
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.镭-223 联合治疗转移性去势抵抗性前列腺癌患者：一项国际性、早期准入、开放标签、单臂 3b 期试验。
Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Epub 2016 Jul 26.
6
Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.在ALSYMPCA中，二氯化镭-223治疗后的化疗。
Prostate. 2016 Jul;76(10):905-16. doi: 10.1002/pros.23180. Epub 2016 Mar 23.
7
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.来自III期ALSYMPCA研究的二氯化镭-223的患者报告生活质量分析。
Ann Oncol. 2016 May;27(5):868-74. doi: 10.1093/annonc/mdw065. Epub 2016 Feb 23.
8
Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride.用二氯化镭-223治疗去势抵抗性前列腺癌和骨转移瘤。
Int J Urol Nurs. 2015 Mar;9(1):3-13. doi: 10.1111/ijun.12059.
9
Prostate cancer.前列腺癌。
Lancet. 2016 Jan 2;387(10013):70-82. doi: 10.1016/S0140-6736(14)61947-4. Epub 2015 Jun 11.
10
Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies.镭-223与新一代抗雄激素疗法联合应用的血液学毒性
Am J Clin Oncol. 2017 Aug;40(4):342-347. doi: 10.1097/COC.0000000000000181.
Zotero 插件